New York, New York (PRWEB) July 02, 2014
As transvaginal mesh lawsuits (http://www.transvaginalmeshlawsuithelp.com/) continue to mount in U.S. courts, Bernstein Liebhard LLP notes that an advocacy group in New Zealand that includes alleged victims of vaginal mesh complications is preparing to ask that country’s Parliament to authorize an inquiry into the risk associated with surgical mesh. According to a report published July 2nd by the Otago Daily Times, Mesh Down Under is demanding action on harmful and painful long-term injuries caused by surgical mesh used in a range of procedures, including pelvic organ prolapse repair. Several members of the group who are scheduled to testify before Parliament's health select committee will also urge the panel to follow Scotland’s lead, and impose a moratorium on the use of mesh in pelvic procedures.*
“Our Firm is representing hundreds of women in transvaginal mesh lawsuits who allegedly suffered injuries similar to those that prompted the members of Mesh Down Under to act. We are pleased that this group is bringing more attention to this issue,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm continues to offer free transvaginal mesh lawsuit reviews to women who suffered mesh erosion, pain, scarring, infection and other serious injuries, allegedly due to products manufactured by American Medical Systems, Inc., Boston Scientific Corp., C.R. Bard, Inc. and Ethicon, Inc.
Vaginal Mesh Lawsuits
According to court documents, more than 60,000 product liability claims have been filed in courts throughout the U.S. by women who allegedly suffered pain, mesh erosion, organ damage and other serious vaginal mesh complications following surgery to treat pelvic organ prolapse or stress urinary incontinence. The U.S. transvaginal mesh litigation began to grow shortly after the U.S. Food & Drug Administration (FDA) launched a review of transvaginal mesh products in October 2008, and alerted the public to the serious risks associated with these devices. In July 2011, the agency issued a second alert after it received thousands of additional reports of injuries associated with these devices. This past April, the FDA proposed reclassifying vaginal mesh used to treat pelvic organ prolapse as high-risk medical devices, which would subject the devices to greater regulatory scrutiny.
Court records indicate that the majority of transvaginal mesh lawsuit filings are pending in several multidistrict litigations underway in the U.S. District Court, Southern District of West Virginia. Bernstein Liebhard LLP partner, Jeffrey S. Grand, is serving on the Plaintiffs’ Steering Committees for a number of these proceedings, including those involving American Medical Systems, Inc. (MDL No. 2325), Boston Scientific Corp. (MDL No. 2326), C.R. Bard, Inc. (MDL No. 2187) and Ethicon, Inc. (MDL No. 2327).
Mr. Grand has also been appointed Co-Liaison Counsel in two multicounty litigations underway in New Jersey Superior Court for transvaginal mesh lawsuits involving products marketed by C.R. Bard and Ethicon. He was also a member of the Plaintiff’s trial team on the first Ethicon trial in that proceeding, which ended in March 2013 with a jury awarding $11 million in compensatory and punitive damages to a woman who was harmed by the Ethicon Gynecare Prolift device. (In re: Pelvic Mesh/Gynecare Litigation, No. 6341-10; In re: Pelvic Mesh Litigation/Bard, No. L-6339-10)
Women who allegedly suffered painful vaginal mesh complications may be entitled to compensation for their injury-related damages. To learn more about filing a transvaginal mesh lawsuit, please visit Bernstein Liebhard LLP's website or the Firm's Facebook page: https://www.facebook.com/meshlawsuit. To obtain a free, confidential and no-obligation case review, please call 800-511-5092.
*odt.co.nz/news/dunedin/307848/group-push-surgical-mesh-inquiry, Otaga Daily Times, July 2, 2014
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs’ Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.
Bernstein Liebhard LLP represents the victims of defective drugs and medical devices on a contingency-fee basis, and our clients are never expected to pay attorneys fees unless their case results in a successful recovery on their behalf. New York State’s contingency fee cap rules generally limit those fees to 33 1/3% of the total recovery. As a result, the Firm’s fees can be significantly lower than those assessed by attorneys in other states, which depending on the law may amount to as much as 40% or more of a plaintiff’s recovery.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq.
Bernstein Liebhard LLP